Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Personalis Awarded US Department of Veterans Affairs Contract for Whole Genome Sequencing and Data Analysis for the Million Veteran Program

Posted on: 06 Oct 16

Personalis, Inc., a precision medicine company focused on genomics solutions for immuno-oncology, cancer, and genetic disease, announced today that the company has been awarded an additional task order by the US Department of Veterans Affairs (VA) to provide whole genome DNA sequencing and data analysis services for the VA’s Million Veteran Program (MVP). Personalis will perform whole genome DNA sequencing, and bioinformatics analysis using its secure computing infrastructure and proprietary algorithms. The sequencing will be performed in Personalis’ recently expanded laboratory in Menlo Park, CA. This additional order will bring the total of whole genome deliveries by Personalis to the VA to over 10,000.

Personalis CEO, John West, said, “We are extremely pleased to continue our relationship with the VA and support the VA’s scientific leadership by providing our high quality whole genome DNA sequencing and data analysis services. As one of the most ambitious medical research sequencing and database efforts in the world, the VA Healthcare System has the opportunity to work toward gaining a better understanding of how genetic variations may affect Veteran health.”

About the VA Million Veteran Program (MVP)

Launched in 2011, MVP is a landmark research effort aimed at better understanding how genetic variations affect health. Up to a million Veterans are expected to enroll in the VA study over the next 4-5 years. Data and genetic samples collected through the study are stored securely and made available for studies by authorized researchers, with stringent safeguards in place to protect Veterans’ private health information. MVP is now enrolling at over 52 VA medical centers nationwide. The VA’s central biorepository is equipped with a state-of-the-art robotic system for DNA extraction and storage and is currently being expanded to support up to 4 million samples. With more than 500,000 enrollees to date, MVP already far exceeds the enrollment numbers of any single VA study or research program in the past, and is in fact one of the largest research cohorts of its kind in the world.

MVP provides researchers with a rich resource of genetic, health, lifestyle, and military-exposure data collected from questionnaires, medical records, and genetic analyses. By combining this information into a single database, MVP promises to advance knowledge about the complex links between genes and health.

Veterans’ privacy and confidentiality are top priorities in MVP, as in all VA research. For more information about MVP, visit

About Personalis, Inc.

Personalis, Inc. ( is a leading precision medicine company focused on advanced NGS-based clinical diagnostic, clinical trial and research services for cancer and inherited genetic disease. Personalis also provides DNA sequencing and data analysis of human genomes.

The Personalis ACE Exome and Transcriptome technology is designed to obtain the most comprehensive and accurate tumor molecular profile for immuno-oncology applications. The company’s clinical laboratory is GCP compliant, CLIA licensed and CAP accredited.

This press release does not imply a Department of Veterans Affairs endorsement, and is neither paid for nor sponsored, in whole or in part, by any element of the United States Government.

View source version on

Business Wire

Last updated on: 06/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.